Adverum Biotechnologies News

Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Cuts Target Price to $16

Moomoo NewsNov 22 14:31 ET · Ratings

Adverum Biotechnologies Price Target Lowered to $16 From $20 at Mizuho

TipRanksNov 22 13:45 ET

Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained

MT NewswiresNov 22 13:28 ET · Ratings

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireNov 20 16:05 ET

Express News | Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

ReutersNov 20 16:05 ET

Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating

Moomoo NewsNov 19 07:33 ET · Ratings

H.C. Wainwright Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsNov 19 03:36 ET · Ratings

Adverum Biotechnologies Advances Ixo-vec Gene Therapy Trials

TipRanksNov 18 16:36 ET

Buy Rating on Adverum Biotechnologies: Ixo-vec's Promising Potential in Transforming Wet AMD Treatment

TipRanksNov 18 12:35 ET · Ratings

Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell

MT NewswiresNov 18 08:16 ET

Express News | Adverum Biotechnologies Inc: 6E10 Dose in Luna Maintains Visual and Anatomic Endpoints

ReutersNov 18 07:03 ET

Express News | Adverum Biotechnologies Inc: Expects to Be Able to Fund Operations Into Second Half of 2025

ReutersNov 18 07:03 ET

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

GlobeNewswireNov 18 07:00 ET

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

GlobeNewswireNov 15 16:05 ET

Adverum Biotechnologies Analyst Ratings

BenzingaNov 5 11:17 ET · Ratings

RBC Capital Initiates Adverum Biotechnologies(ADVM.US) With Hold Rating, Announces Target Price $10

Moomoo NewsNov 5 08:36 ET · Ratings

TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating

Moomoo NewsNov 5 08:36 ET · Ratings

Adverum Biotechnologies Price Target Lowered to $10 From $12 at RBC Capital

TipRanksNov 5 08:00 ET

A Quick Look at Today's Ratings for Adverum Biotechnologies(ADVM.US), With a Forecast Between $10 to $30

Moomoo NewsNov 5 08:00 ET · Ratings

Buy Rating on Adverum Biotechnologies Driven by Ixo-vec's Promising Data and Potential Impact on AMD Treatment

TipRanksNov 5 06:25 ET · Ratings